Pfizer’s most recent trend suggests a bullish bias. One trading opportunity on Pfizer is a Bull Put Spread using a strike $30.00 short put and a strike $25.00 long put offers a potential 5.49% return on risk over the next 25 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $30.00 by expiration. The full premium credit of $0.26 would be kept by the premium seller. The risk of $4.74 would be incurred if the stock dropped below the $25.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Pfizer is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Pfizer is bullish.
The RSI indicator is at 69.11 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Pfizer
Eli Lilly’s Q3 beats on top and bottom line
Wed, 23 Oct 2013 11:17:00 GMT
CNBC – We had strong revenue growth of six-percent, and three-percent of that growth was volume driven, says Derica Rice, Eli Lilly CFO, breaking down his company’s Q3 results and discussing several products …
Johnson & Johnson’s FDA Bounce Propels the Dow Higher
Tue, 22 Oct 2013 18:46:18 GMT
Motley Fool – The Dow Jones has retreated from triple-digit gains as Pfizer and Johnson & Johnson help keep the index in the green.
Billionaire Ken Fisher’s 3 Top Stock Picks
Tue, 22 Oct 2013 17:58:04 GMT
Motley Fool – See which stocks are this hedge fund manager’s favorites.
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
Tue, 22 Oct 2013 16:53:00 GMT
PR Newswire – LONDON, Oct. 22, 2013 /PRNewswire/ — ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, …
CVS tries pushing loyalty cards to next level
Tue, 22 Oct 2013 16:41:57 GMT
Big Data Download – http://d.yimg.com/hd/cnbc2/lotus/1382457146138_750_21yFZqoPjnbf1_1_0.jpg?s=761160f74557888c3f0857388db47b94&c=34e4cff4b772b752720e9252feba28af&a=cnbc2&mr=0
Also on Market Tamer…
Follow Us on Facebook